Global EditionASIA 中文双语Français
China
Home / China / Health

COVID treatment Molnupiravir approved for import in China

By Wang Xiaoyu | chinadaily.com.cn | Updated: 2022-12-30 20:58
Share
Share - WeChat

China's top drug regulator said on Friday that it has granted conditional market approval for the import of Merck's COVID-19 treatment, Molnupiravir.

The National Medical Products Administration said that the oral COVID-19 pill will be used to treat adult COVID-19 patients at risk of developing serious symptoms, such as the elderly, obese or overweight patients and those with chronic kidney disease, diabetes, serious cardiovascular diseases, chronic obstructive pulmonary diseases, or cancer.

With the newly issued approval, three COVID-19 pills have become available in China. The other two are Pfizer's Paxlovid and the domestically developed Azvudine.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US